GP方案动静脉联合化疗中晚期中央型肺癌临床疗效评价

目的：评价吉西他滨联合顺铂（GP）方案经支气管动脉灌注联合全身化疗中晚期中央型肺癌疗效评价及不良反应。资料与方法：Ⅲ期中央型肺癌患者60例，随机分为两组。每组30例。支气管动脉灌注化疗（BM）组：吉西他滨1000mg／m^2＋顺铂80mg／m^2第一天经支气管动脉灌注化疗，吉西他滨1000mg／m^2第八天静脉滴注；全身化疗组：吉西他滨1000mg／m^2第1、8天、顺铂80mg／m2第1天静脉滴注，两组均21天为一周期，两周期后评价疗效。结果：BAI组和全身化疗组的有效率为36．7％和73．3％、临床获益率93．3％和67．7％，BAI组不良反应明显低于全身化疗组。结论：GP方案经支气管动脉灌注联合全身化疗中晚期中央型肺癌近期疗效显著，毒副反应轻微。

Clinical Study of Gemcitabine plus Cisplatin Combining Bronchial Artery Infusion and Systemic Chemotherapy for Non- small Cell Lung Cancer in Middle- Later Stage

Objective： To compare the efficacy, side - effect and toxicity between bronchial artery infusion （BAI） of gemcitabine plus cisplatin combining systemic chemotherapy and stem- ic chemotherapy only for advanced non - small cell lung cancer （NSCLC）. Methods：The 60 patients with NSCLC in stage Ⅲ were divided randomly into treatment and control group, In inter- ventional treatment group：the gemcitabine 1000mg/m2 and cis- platin 80mg/m2 was infused from bronchial arterial on 1 st day, and gemcitabine 1000mg/m2 was infused from vein on 8th day. The systemic chemotherapy group with gemcitabine 1000mg/m2 was infused from vein on 1st and 8th, and cisplatin 80mg/m2 on 1st respectively, repeated every 21 days as one cy- cle, all patients received at least 2 Cycles. Results：The effective and clinical beneficial rate was 67. 7% vs 36.7% and 93. 3.0% vs 73.3% respectively in BAI and systemic chemotherapy group. The incidence of side effects was lower in interventional therapy group than systemic chemotherapy group. Conclusion： The effective and clinical bene~qcial rate was higher in interventional therapy group than systemic chemotherapy group of ad- vanced non - small cell lung cancer（NSCLC） and the incidence of side effects was lower.